tbuckley/cabot-search huggingface dataset:
Addition of Nonauthor Collaborators and a Supplement
Journal: JAMA Neurology (2024)

Jacqueline A. French, MD; Roger J. Porter, MD; Emilio Perucca, MD, PhD; Martin J. Brodie, MD; Michael A. Rogawski, MD, PhD; Simon Pimstone, MD, PhD; Ernesto Aycardi, MD; Cynthia Harden, MD; Jenny Qian, MS; Constanza Luzon Rosenblut, MD; Christopher Kenney, MD; Gregory N. Beatch, PhD; X-TOLE Study Group; Robert Armstrong; Ekrem Kutluay; Pavel Klein; Toufic Fakhoury; Kore Liow; Stephen Flitman; Victor Biton; Michael Sperling; David Kudrow; Mercedes Jacobson; Kamil Detyniecki; Fawad Ahmed Khan (Prev: Ramsay); Evan Fertig; Ahmad Saeed Ata; Dean Naritoku; Bassel Abou-Khalil; Sasha Alick; Sami Aboumatar; Stephanie Callow (Prev: Moseley); Shahram Izadyar (Prev: Beach) ; Robert Wechsler; Jerzy Szaflarski; Nathan Fountain; Imran Ali; George Li; Theresa Rodgers-Neame; Elizabeth Waterhouse; Selim Benbadis; Steve Chung; Maria Sam; Joanne Rogin; Eric Segal; Claude Steriade; Amir Arain; Richard Pellegrino; Kenneth Laxer; Mushtaque Chachar; Conrad Nievera Jr.; Max Benzaquen; David Gloss; Ahmed Sadek; Lixin Zhang; Wei Ma; Aashit Shah; James Valeriano; Heidi Henninger; Jeffrey Tsai (Prev: Miller); Brian Moseley; Ruben Kuzniecky; Jerry Shih; Gregory Cascino; Alberto Pinzon-Ardila; Elizabeth Gerard; Samiya Rashid; Utku Uysal; Samuel Destefano .; William Tatum; Suparna Krishnaiengar (Prev: Bautista); Raymond Faught Jr.; Eric Geller; Rolando Ania; Baljeet Sethi; Barbara Phillips; Micaela Chatman; Eric Segal(Satellite) ; Andrew Lerman; Naoir Zaher; Ricardo Ayala; Michael Gelfand; David Lesch; David Vossler; Paul Lyons; Ruben Kuzniecky (Satellite) ; David Steiner; Martin del Campo; Jean-François Clement; Seyed Mirsattari; Mary Connolly; Craig Heath; Mark Richardson; Khalid Hamandi; Elizabeth Galizia; Kathleen White; Anthony Marson; Rhys Thomas; Bernhard Steinhoff; Christian Brandt; Holger Lerche; Rainer Surges; Christoph Kellinghaus; Gabriel Moeddel; Rebekka Lehmann; Felix Rosenow; Thomas Mayer; Andreas Schulze-Bonhage ; Christian Tilz; Manuel Toledo; Vicente Villanueva; Juan Carlos Sanchez; Pedro Serrano-Castro; Rodrigo Rocamora; Rosa Ana Saiz-Diaz; Maria Centeno; Juan Rodriguez-Uranga; Jose Serratosa; Antonio Gil-Nagel (Prev: Aledo; Juan Luis Becerra; Javier López-González; Dulce Campos ; Violeta Sanchez; Manuel Simon-Talero; Irene Garcia Morales; Rafael Toledano; Vitalie Lisnic; Sergii Kharchuk; Umberto Aguglia ; Carlo Galimberti; Laura Canafoglia; Antonio Gambardella; Francesca Bisulli; Chiara Pizzanelli; Carlo Di Bonaventura; Roman Shakarishvili
Time to Continuous Renal Replacement Therapy Initiation and 90-Day Major Adverse Kidney Events in Children and Young Adults
Authors: Katja M. Gist, Shina Menon, Pilar Anton-Martin, Amee M. Bigelow, Gerard Cortina, Akash Deep, Sara De la Mata-Navazo, Ben Gelbart, Stephen Gorga, Isabella Guzzo, Kenneth E. Mah, Nicholas J. Ollberding, H. Stella Shin, Sameer Thadani, Amanda Uber, Huaiyu Zang, Michael Zappitelli, David T. Selewski, Emily Ahern, Ayse Akcan Arikan, Issa Alhamoud, Rashid Alobaidi, Shanthi S Balani, Matthew Barhight, Abby Basalely, Gabriella Bottari, Andrea Cappoli, Eileen A Ciccia, Michaela Collins, Denise Colosimo, Mihaela A Damian, Gabrielle DeAbreu, Kathy L Ding, Kristin J Dolan, Sarah N Fernandez LaFever, Dana Y Fuhrman, Francesco Guzzi, Taiki Haga, Elizabeth Harvey, Denise C Hasson, Taylor Hill-Horowitza, Haleigh Inthavong, Catherine Joseph, Ahmad Kaddourah, Aadil Kakajiwala, Aaron D Kessel, Sarah Korn, Kelli A Krallman, David M Kwiatkowski, Jasmine Lee, Laurance Lequier, Tina Madani Kia, Eleonora Marinari, Susan D Martin, Tahagod H Mohamed, Catherine Morgan, Theresa Mottes, Melissa A Muff-Luett, Siva Namachivayam, Tara M Neumayr, Jennifer Nhan, Abigail O'Rourke, Matthew G Pinto, Dua Qutob, Valeria Raggi, Stephanie Reynaud, Zaccaria Ricci, Zachary A Rumlow, María J Santiago Lozano, Emily See, Carmela Serpe, Alyssa Serratore, Ananya Shah, Weiwen V Shih, Cara L Slagle, Sonia Solomon, Danielle E Soranno, Rachana Srivastava, Natalja L Stanski, Michelle C Starr, Erin K Stenson, Amy E Strong, Susan A Taylor, Brynna Van Wyk, Tennille N Webb, Emily E Zangla
Journal: JAMA Network Open (2024)

In clinical trials, the early or accelerated continuous renal replacement therapy (CRRT) initiation strategy among adults with acute kidney injury or volume overload has not demonstrated a survival benefit. Whether the timing of initiation of CRRT is associated with outcomes among children and young adults is unknown.
Lifetime Gained With Cancer Screening
Authors: Ernst J. Kuipers, Manon C. W. Spaander
Journal: JAMA Internal Medicine (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection
Authors: Nicole Frumento, Ariadne Sinnis-Bourozikas, Harry T. Paul, Georgia Stavrakis, Muhammad N. Zahid, Shuyi Wang, Stuart C. Ray, Andrew I. Flyak, George M. Shaw, Andrea L. Cox, Justin R. Bailey
Journal: Immunity (2024)

Individuals who clear primary hepatitis C virus (HCV) infections clear subsequent reinfections more than 80% of the time, but the mechanisms are poorly defined. Here, we used HCV variants and plasma from individuals with repeated clearance to characterize longitudinal changes in envelope glycoprotein E2 sequences, function, and neutralizing antibody (NAb) resistance. Clearance of infection was associated with early selection of viruses with NAb resistance substitutions that also reduced E2 binding to CD81, the primary HCV receptor. Later, peri-clearance plasma samples regained neutralizing capacity against these variants. We identified a subset of broadly NAbs (bNAbs) for which these loss-of-fitness substitutions conferred resistance to unmutated bNAb ancestors but increased sensitivity to mature bNAbs. These data demonstrate a mechanism by which neutralizing antibodies contribute to repeated immune-mediated HCV clearance, identifying specific bNAbs that exploit fundamental vulnerabilities in E2. The induction of bNAbs with these specificities should be a goal of HCV vaccine development.
Problem-Solving Skills Training for Parents of Children With Chronic Health Conditions
Authors: Tianji Zhou, Yuanhui Luo, Wenjin Xiong, Zhenyu Meng, Hanyi Zhang, Jingping Zhang
Journal: JAMA Pediatrics (2024)

Problem-solving skills training (PSST) has a demonstrated potential to improve psychosocial well-being for parents of children with chronic health conditions (CHCs), but such evidence has not been fully systematically synthesized.
Outcomes Following Adherence to a Randomized Stroke Trial Protocol
Authors: Rolf Ankerlund Blauenfeldt, Claus Z. Simonsen, Jan B. Valentin, Søren P. Johnsen, Niels Hjort, Grethe Andersen
Journal: JAMA Network Open (2024)

This secondary analysis of a randomized clinical trial assesses whether compliance with the study protocol is associated with a better functional outcome even among participants in the sham-control group.
Advance Provision of Mifepristone and Misoprostol via Online Telemedicine in the US
Authors: Abigail R. A. Aiken, Jennifer E. Starling, Daniëlle C. van Blitterswijk, Carlijn Looijen, Thijs van Vliet, Dirk R. Essink, Rebecca Gomperts
Journal: JAMA Internal Medicine (2024)

This cross-sectional study examines trends in the demand and characteristics and motivations of individuals who requested advance provision of abortion medications.
Manifesto Calls upon UK to Cut 20,000 Cancer Deaths a Year
Authors: Suzanne Rose
Journal: Cancer Discovery (2023)

Britain’s Cancer Research UK (CRUK) published a five-point plan to help boost research funding, reduce cancer mortality rates, prevent thousands of cancers, and improve patient survival. The charity says if the next UK government implements its recommendations, about 20,000 fewer people would die of cancer every year by 2040.
Thrombectomy With the pRESET vs Solitaire Stent Retrievers as First-Line Large Vessel Occlusion Stroke Treatment
Authors: Raul G. Nogueira, Donald Lobsien, Joachim Klisch, Daniel Pielenz, Elmar Lobsien, Eric Sauvageau, Nima Aghaebrahim, Markus Möhlenbruch, Dominik Vollherbst, Christian Ulfert, Hormozd Bozorgchami, Wayne Clark, Ryan Priest, Edgar A. Samaniego, Santiago Ortega-Gutierrez, Malik Ghannam, Demetrius Lopes, Joshua Billingsley, Kiffon Keigher, Diogo C. Haussen, Alhamza R. Al-Bayati, Adnan Siddiqui, Elad Levy, Michael Chen, Stephan Munich, Peter Schramm, Tobias Boppel, Sandra Narayanan, Bradley A. Gross, Christian Roth, Tobias Boeckh-Behrens, Ameer Hassan, Johanna Fifi, Ron F. Budzik, Jason Tarpley, Robert M. Starke, Eytan Raz, Gary Brogan, David S. Liebeskind, Ricardo A. Hanel
Journal: JAMA Neurology (2024)

Stent retriever-based thrombectomy is highly beneficial in large vessel occlusion (LVO) strokes. Many stent retriever designs are currently available, but comparison of these technologies in well-conducted studies is lacking.
Multi-omics integration identifies cell-state-specific repression by PBRM1-PIAS1 cooperation
Authors: Patric J. Ho, Junghun Kweon, Laura A. Blumensaadt, Amy E. Neely, Elizabeth Kalika, Daniel B. Leon, Sanghyon Oh, Cooper W.P. Stringer, Sarah M. Lloyd, Ziyou Ren, Xiaomin Bao
Journal: Cell Genomics (2024)

PBRM1 is frequently mutated in cancers of epithelial origin. How PBRM1 regulates normal epithelial homeostasis, prior to cancer initiation, remains unclear. Here, we show that PBRM1's gene regulatory roles differ drastically between cell states, leveraging human skin epithelium (epidermis) as a research platform. In progenitors, PBRM1 predominantly functions to repress terminal differentiation to sustain progenitors' regenerative potential; in the differentiation state, however, PBRM1 switches toward an activator. Between these two cell states, PBRM1 retains its genomic binding but associates with differential interacting proteins. Our targeted screen identified the E3 SUMO ligase PIAS1 as a key interactor. PIAS1 co-localizes with PBRM1 on chromatin to directly repress differentiation genes in progenitors, and PIAS1's chromatin binding drastically diminishes in differentiation. Furthermore, SUMOylation contributes to PBRM1's repressive function in progenitor maintenance. Thus, our findings highlight PBRM1's cell-state-specific regulatory roles influenced by its protein interactome despite its stable chromatin binding.
Lifetime Gained With Cancer Screening
Authors: Jennifer A. Watt, Areti-Angeliki Veroniki, Sharon E. Straus
Journal: JAMA Internal Medicine (2024)

To the Editor We read the article by Bretthauer et al1 with interest. Of late, there is intense focus on the merits of cancer screening and the need to effectively deploy cancer screening programs in diverse populations. This article advances the discussion on this important and timely topic.
Recommendations for Reporting Research About Racial Disparities in Medical and Scientific Journals
Authors: Andrea F. Duncan, Diana Montoya-Williams
Journal: JAMA Pediatrics (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Utilization of Cryopreserved Oocytes in Patients With Poor Ovarian Response After Planned Oocyte Cryopreservation
Authors: Yuval Fouks, Denny Sakkas, Pietro E. Bortoletto, Alan S. Penzias, Emily A. Seidler, Denis A. Vaughan
Journal: JAMA Network Open (2024)

Importance Poor ovarian response (POR) to stimulation may impact patients’ desire or need to utilize cryopreserved oocytes for family building in the future. These findings, captured by Society for Assisted Reproductive Technology (SART) national data, underscore the need for tailored counseling and further research into the decision-making processes influencing oocyte utilization. Objective To examine the association of ovarian response to stimulation and the number of vitrified oocytes with the likelihood and timing of patients returning for oocyte utilization following planned oocyte cryopreservation (OC). Design, Setting, and Participants This cohort study used data in the SART Clinical Outcome Reporting System for patients in US fertility clinics and data was used for eligible patients who underwent planned OC from January 2014 through December 2020. Data were analyzed from November 2022 to June 2023. Main outcomes and measures The association between number of oocytes cryopreserved on return rate to utilize cryopreserved oocytes and the time from vitrification to warming. Results A total of 67 893 autologous oocyte freezing cycles were performed in the US between 2014 and 2020, among 47 363 patients (mean [SD] age, 34.5 [4.7] years). Of these, 6421 (13.5%) were classified as patients with POR, with fewer than 5 oocytes vitrified across all ovarian stimulation cycles. A total of 1203 patients (2.5%) returned for oocyte warming and utilization. The rate of return was significantly higher in the POR group, with 260 (4.0%) returning compared with 943 (2.3%) in the normal responder group ( P &amp;amp;lt; .001). This trend was most notable in the age 30 to 34 years (warm cycle, 46 of 275 [16.7%] vs no warm cycle, 982 of 11 743 [8.4%]; P &amp;amp;lt; .001) and age 35 to 39 years groups (warm cycle, 124 of 587 [21.1%] vs no warm cycle, 3433 of 23 012 [14.9%]; P &amp;amp;lt; .001). The time elapsed from vitrification to warming was comparable between patients with POR (mean [SD], 716.1 [156.1] days) and normal responders (803.8 [160.7] days). A multivariate analysis adjusted for age, clinic region in the US, body mass index, and history of endometriosis was conducted to identify factors associated with the utilization of oocytes. The analysis revealed that having fewer than 5 oocytes vitrified was associated with higher odds of utilizing oocytes (OR, 1.52; 95% CI, 1.32-1.76). Conclusions and Relevance This cohort study reveals a distinct pattern in the utilization of cryopreserved oocytes among patients undergoing planned OC in the US. Despite the increase in number of patients pursuing OC, there is a notably low rate of return to utilize previously vitrified oocytes; notably, patients with POR are more likely to return, although the time to return is similar to those with normal ovarian response.
Automated External Defibrillators Are Only Effective If Put to Use
Authors: Isabel Ostrer, Tracy Y. Wang
Journal: JAMA Internal Medicine (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Squishy matters – Corneal mechanobiology in health and disease
Authors: Sara M. Thomasy, Brian C. Leonard, Mark A. Greiner, Jessica M. Skeie, Vijay Krishna Raghunathan
Journal: Progress in Retinal and Eye Research (2024)

The cornea, as a dynamic and responsive tissue, constantly interacts with mechanical forces in order to maintain its structural integrity, barrier function, transparency and refractive power. Cells within the cornea sense and respond to various mechanical forces that fundamentally regulate their morphology and fate in development, homeostasis and pathophysiology. Corneal cells also dynamically regulate their extracellular matrix (ECM) with ensuing cell-ECM crosstalk as the matrix serves as a dynamic signaling reservoir providing biophysical and biochemical cues to corneal cells. Here we provide an overview of mechanotransduction signaling pathways then delve into the recent advances in corneal mechanobiology, focusing on the interplay between mechanical forces and responses of the corneal epithelial, stromal, and endothelial cells. We also identify species-specific differences in corneal biomechanics and mechanotransduction to facilitate identification of optimal animal models to study corneal wound healing, disease, and novel therapeutic interventions. Finally, we identify key knowledge gaps and therapeutic opportunities in corneal mechanobiology that are pressing for the research community to address especially pertinent within the domains of limbal stem cell deficiency, keratoconus and Fuchs' endothelial corneal dystrophy. By furthering our understanding corneal mechanobiology, we can contextualize discoveries regarding corneal diseases as well as innovative treatments for them.
CD4+ T cell immunity is dependent on an intrinsic stem-like program
Authors: Dawei Zou, Zheng Yin, Stephanie G. Yi, Guohua Wang, Yang Guo, Xiang Xiao, Shuang Li, Xiaolong Zhang, Nancy M. Gonzalez, Laurie J. Minze, Lin Wang, Stephen T. C. Wong, A. Osama Gaber, Rafik M. Ghobrial, Xian C. Li, Wenhao Chen
Journal: Nature Immunology (2024)
Accounting for diverse transposable element landscapes is key to developing and evaluating accurate de novo annotation strategies
Authors: Landen Gozashti, Hopi E. Hoekstra
Journal: Genome biology (2024)

Abstract Transposable elements (TEs) are important drivers of genome evolution. Nonetheless, TE annotation remains a complex and challenging task. As more genomes from phylogenetically diverse species are published, a comprehensive pipeline for accurate annotation of diverse TEs is increasingly important. Recently, (Ou et al. Genome Biol. 20:275, 2019) developed a new comprehensive pipeline, Extensive De novo Transposable element Annotator (EDTA), and benchmarked its performance on the genomes of three species: maize, wheat, and fruit fly. Because TE landscapes can vary tremendously across species, we tested EDTA’s performance on four additional genomes with different TE landscapes: mouse, zebrafish, zebra finch, and chicken. Our analysis reveals that EDTA faces challenges with repeat classification in these genomes and underperforms overall relative to its benchmark dataset. Notably, EDTA consistently misclassifies nonLTR retrotransposons as DNA transposons, resulting in erroneous TE annotations for species with considerable repertoires of nonLTR retrotransposons. Overall, we set expectations for EDTA’s performance on genomes spanning additional diversity, urge caution when using EDTA on genomes with divergent TE repertoires from the species on which it was initially benchmarked, and hope to motivate the development of methods that are robust to both the diversity of TEs and TE landscapes observed across species.
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer
Authors: Ana Oaknin, Sharad A. Ghamande, Yuka Kasamatsu, Marta Gil-Martin, Juan Francisco Grau-Bejar, Carmen Garcia-Duran, Masashi Sato, Abdul Siddiqui, Surendra Pal Chaudhary, Yulia Vugmeyster, Kosei Hasegawa
Journal: Clinical Cancer Research (2024)

Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGFβ receptor II (a TGFβ "trap") fused to a human IgG1 mAb blocking programmed death-ligand 1 (PD-L1), was evaluated as treatment in patients with locally advanced or persistent, recurrent, or metastatic (P/R/M) cervical cancer.
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Authors: Shinji Nakamichi, Kaoru Kubota, Toshihiro Misumi, Tetsuro Kondo, Shuji Murakami, Yoshimasa Shiraishi, Hisao Imai, Daijiro Harada, Kazutoshi Isobe, Hidetoshi Itani, Saori Takata, Hiroshi Wakui, Yuki Misumi, Satoshi Ikeda, Tetsuhiko Asao, Naoki Furuya, Shinobu Hosokawa, Yumiko Kobayashi, Yuichi Takiguchi, Hiroaki Okamoto
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Concurrent chemoradiotherapy (CCRT) followed by durvalumab consolidation for up to 12 months is the standard of care for patients with unresectable stage III non–small cell lung cancer (NSCLC). However, exactly when to initiate durvalumab therapy after chemoradiation completion remains unknown. We evaluated the efficacy and safety of durvalumab, administered immediately after CCRT completion, for patients with unresectable stage III NSCLC. Patients and Methods: This study was a prospective, single-arm, open-label phase II clinical trial. Patients without disease progression after definitive CCRT (two cycles of platinum-based doublet chemotherapy with 60 Gy/30 Fr radiotherapy) received durvalumab (every 2 weeks for up to 12 months) from the next day (up to 5 days) after the final radiation dose. The primary endpoint was the 1-year progression-free survival (PFS) from registration before the start of CCRT. Results: From January 2020 to August 2020, 47 of 50 enrolled patients were evaluable for treatment efficacy and safety. The 1-year PFS from registration was 75.0% [60% confidence interval (CI), 69.0–80.0 and 95% CI, 59.4–85.3]. The objective response rate throughout the study treatment and median PFS from registration were 78.7% and 14.2 months (95% CI, 13.4 to not reached), respectively. Grade 3/4 pneumonitis and febrile neutropenia were each 4.3%. Conclusions: Our study met the primary endpoint. The incidence of pneumonitis was similar to that of a Japanese subset in the PACIFIC study. Our data support the efficacy and safety of durvalumab administered immediately after the completion of CCRT for patients with unresectable stage III NSCLC.